Multi-receptor pharmacology and the scope of published safety evidence
In human-receptor assays compiled by Yuan & Tao (2022) (Kievit et al., 2013), Melanotan II activates MC1R (0.2 nM), MC3R (0.51 nM), MC4R (0.05 nM), and MC5R (5.33 nM) with nanomolar to subnanomolar potency. As Böhm et al. (2025) note, because Melanotan II can cross the blood–brain barrier and is nonselective, it activates other melanocortin receptors, yielding events such as fatigue, loss of appetite, and penile erection.
In a February 2026 PRISMA systematic review of 68 peer-reviewed studies across self-tanning agents—dihydroxyacetone (DHA), melanotan, forskolin, and carotenoids—Resnick et al. (2026) reported rhabdomyolysis, renal infarction, and priapism in their discussion of unregulated melanotan I and II use. Because online melanotan products are unlicensed and incompletely tested, published human safety data come mainly from individual clinical case reports and dermatologic case series—records that document severe clinical diagnoses presenting after exposure but cannot establish population incidence rates.
Acute systemic, urologic, vascular, and oral mucosal case reports
- Sympathomimetic toxidrome and rhabdomyolysis: In a single-patient emergency-department case report, Nelson et al. (2012) described a 39-year-old man arriving two hours after exposure to internet-purchased Melanotan II (confirmed as Melanotan II by mass spectrometry against a reference standard). Exam showed restlessness, anxiety, mydriasis, diaphoresis, diffuse muscle tremors, blood pressure 151/85 mmHg, and heart rate 130 bpm peaking at 146 bpm; hospital diagnostic laboratory values showed creatinine 2.25 mg/dL, troponin 0.23 ng/mL, white blood cells 19.1 k/μL, and creatine phosphokinase (CPK) climbing from 1,760 IU/L to 17,773 IU/L 12 hours into ICU admission. Treated with intravenous fluids and sodium bicarbonate over a 3-day ICU stay, his diagnostic CPK fell to 2,622 IU/L and creatinine improved to 1.23 mg/dL at discharge; the authors diagnosed apparent sympathomimetic symptoms, rhabdomyolysis, and renal dysfunction resulting from Melanotan II use.
- Ischemic priapism with lasting dysfunction: Dreyer et al. (2019) diagnosed low-flow priapism in an adult male presenting after melanotan exposure; managed with cavernosal aspiration, irrigation, and phenylephrine, he avoided surgical shunting but had not recovered erectile function at 4-week follow-up. Separately, Mallory et al. (2021) diagnosed refractory ischemic priapism in a 55-year-old man arriving with a 30-hour painful erection after Melanotan II exposure; after failing bedside phenylephrine, he underwent operative penoscrotal decompression and had corpora fibrosis and new-onset erectile dysfunction (rigidity 4/10) at 15-week follow-up.
- Renal infarction and PRES: Peters et al. (2020) reported a clinical diagnosis of renal infarction, which the authors most likely attributed to Melanotan II while noting possible thrombotic pharmacological influence and direct renal parenchymal toxicity. Kaski et al. (2013) reported posterior reversible encephalopathy syndrome (PRES) alongside melanotan exposure—an event also cited in FDA's April 22, 2026 compounding safety text, while Australia's TGA (January 24, 2025) notes: “With melanotan-II, there have been reports of increased moles and freckles, kidney dysfunction and swelling of the brain.”
- Oral mucosal pigmentation: Bonchev (2026) examined a patient after 64 days of Melanotan II exposure and diagnosed brown pigmentation on the attached maxillary and mandibular gums (gingiva) plus irregular patches on both inner cheeks (buccal mucosa). Because the oral cavity is largely shielded from UV radiation, the authors considered systemic melanocortin activity a possible explanation for the discoloration; follow-up documented cheek pigmentation that nearly disappeared at one month and less intense gum pigmentation at three months.
| Clinical Diagnosis | Case Profile & Attribution | Recorded Markers & Follow-Up | Primary Source |
|---|---|---|---|
| Sympathomimetic symptoms & rhabdomyolysis | Single case report: 39-year-old man; MS-confirmed MT-II | Hospital vitals & diagnostic lab values: HR 146 bpm, BP 151/85 mmHg, creatinine 2.25 mg/dL, peak CPK 17,773 IU/L; 3-day ICU | Nelson et al. (2012) |
| Refractory ischemic priapism | 55-year-old man; onset after MT-II exposure | 30-hour duration; penoscrotal decompression; fibrosis & ED at 15 wk | Mallory et al. (2021) |
| Low-flow priapism | Adult male ED presentation after melanotan | Aspiration, irrigation & phenylephrine; ED unresolved at 4 wk | Dreyer et al. (2019) |
| Renal infarction | Single case; most likely attributed to MT-II | Possible thrombotic or direct parenchymal mechanism proposed | Peters et al. (2020) |
| Oral mucosal pigmentation | 64-day MT-II exposure; systemic activity proposed | Cheek pigment nearly gone at 1 mo; less intense gum pigment at 3 mo | Bonchev (2026) |
| Five primary melanomas in situ | 49-year-old man (Fitzpatrick II); MT-II + ~12 sunbed sessions; causality unproven | Histology confirmed 5 melanomas in situ in severely dysplastic nevi | Vadner & Smith (2026) |
Darkening moles and the melanoma causality audit
First, unregulated use alters pigmented lesions. Reviews note case reports linking unregulated Melanotan I and II to melanocytic changes in existing moles and newly emerging dysplastic nevi, complicating skin exams (Langan et al., 2010).
Second, melanoma diagnoses reported after Melanotan II carry major confounders. Habbema et al. (2017) summarized four reports of melanomas emerging from existing moles during or shortly after melanotan use, including a 20-year-old Fitzpatrick II woman combining 3 to 4 weeks of MT-II with sunbed tanning. Böhm et al. (2025) counted at least five melanoma reports during or after Melanotan II—all with other risk factors such as fair skin, excess sun or tanning-bed use, or family history, including a 23-year-old red-haired woman with three melanomas whose genetic testing revealed heterozygous gene variants in MC1R and CDKN2A, a high-risk melanoma-associated gene. In 2026, Vadner & Smith (2026) diagnosed five primary melanomas in situ in a 49-year-old Fitzpatrick II man who paired online Melanotan II with about 12 tanning-bed sessions and anabolic hormone use.
Third, single observational cases cannot prove causation. Vadner & Smith (2026) note that rapid pigment darkening can unmask preexisting melanomas, frequent tanning-bed exposure is a major independent confounder, and online product composition and purity were unverified. Conversely, Böhm et al. (2025) (disclosing Rhythm Pharmaceuticals editorial support) report that more than 1,000 patients exposed to prescription afamelanotide—many for 5 years and some for over 10 years—had no melanoma events reported, while cautioning that chronic MC1R activation does not serve as complete prevention.